Tag Archives: hard-to-drug targets

ICR Scientists Develop Pathfinder Molecules Targeting DHX8 in Cancer Drug Discovery

Posted on 7, August 2026 by EuropaWire PR Editor

(IN BRIEF) Researchers at The Institute of Cancer Research, London, working with Merck KGaA, have developed the first potent small-molecule inhibitors of DHX8, an enzyme involved in pre-mRNA splicing. The compounds are described as “pathfinder molecules” rather than drug candidates, … Read the full press release →

Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom

Tagged biochemical tests, cancer biology, cancer diversity, Cancer Drug Discovery, cancer evolution, Cancer Research UK, cancer stress responses, cancer-selective therapeutic window, Centre for Cancer Drug Discovery, chemical probes, compound 53, crystal structure, DEAH-box RNA helicases, DHX8, Dr Rob van Montfort, drug resistance, fragment-based drug design, gene expression, hard-to-drug targets, helicase domain, Hit Discovery and Structural Design Group, HSF1, ICR, ICR and Merck KGaA Advance Fragment-Based Approach to Target DHX8, Journal of Medicinal Chemistry, lung cancer cells, Medicinal Chemistry, Merck KGaA, mRNA splicing, nanomolar concentrations, New Small-Molecule Inhibitors Open Route to Underexplored RNA Helicase Cancer Targets, oncogenes, pathfinder molecules, Pathfinder Molecules Show Potential to Unlock New Family of Cancer Drug Targets, pre-mRNA splicing, protein translation, RNA binding, RNA helicase family, RNA processing, RNA-competitive inhibitors, small molecule inhibitors, spliceosome, structural biology, structure-guided medicinal chemistry, target engagement, The Institute of Cancer Research London, therapeutic cancer targets, underexploited drug targets, X-ray crystallography